CriticalTriptan, selective 5HT1B/1D receptor agonist×Selective 5-HT1B/1D serotonin receptor agonist
Updated · Methodology
Mechanism
Rizatriptan and naratriptan are selective agonists of the 5-HT1B and 5-HT1D serotonin receptors that mediate constriction of cranial blood vessels (rizatriptan and naratriptan summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Their effects add up, and according to the Spanish rizatriptan SmPC this raises the risk of coronary artery constriction and hypertensive effects (AEMPS, section 4.5). The Spanish naratriptan SmPC states that data on combinations with ergotamine, dihydroergotamine or sumatriptan are limited and that a higher risk of coronary vasospasm with 5-HT1 agonists is a theoretical possibility (AEMPS, section 4.5). The US labels of both drugs give possible additive vasospastic effects as the reason for the contraindication (US Food and Drug Administration, FDA, sections 7.2 and 7.3). The documents give no data on either drug changing the levels of the other: monoamine oxidase A is the main enzyme that breaks down rizatriptan, and naratriptan did not inhibit monoamine oxidase in vitro (rizatriptan and naratriptan SmPCs, AEMPS, sections 4.5 and 5.2).
Symptoms
Agonists of 5-HT1B/1D receptors have been associated with coronary artery spasm and, rarely, with myocardial ischaemia and infarction (rizatriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Each of the two drugs can itself cause palpitations, raised blood pressure and transient chest tightness and pain, sometimes intense and spreading to the throat. After naratriptan, ischaemic colitis is rare, and coronary vasospasm, angina, myocardial infarction and peripheral vascular ischaemia are very rare (rizatriptan and naratriptan SmPCs, AEMPS, sections 4.4 and 4.8). Life-threatening ventricular tachycardia and ventricular fibrillation have been reported within a few hours of 5-HT1 agonists, and on rare occasions hypertensive crisis with acute impairment of organ systems. Spasm of other arteries causes ischaemia of the limbs and bowel, with abdominal pain and bloody diarrhoea (rizatriptan and naratriptan labels, US Food and Drug Administration, FDA, sections 5.2, 5.5 and 5.8).
Management
The combination is contraindicated. The Spanish rizatriptan summary of product characteristics (SmPC) names naratriptan among the 5-HT1B/1D receptor agonists that must not be used with rizatriptan (Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5), and the Spanish naratriptan SmPC contraindicates naratriptan with any triptan (AEMPS, section 4.3). The US labels of both drugs contraindicate a second 5-HT1 agonist within 24 hours (US Food and Drug Administration, FDA, sections 4, 7.2 and 7.3). Keep at least 24 hours between the two drugs, in either order (FDA labels, section 4). The Spanish naratriptan SmPC sets the same 24 hours after naratriptan before any other triptan (AEMPS, section 4.5), and the Spanish rizatriptan SmPC gives no such interval. If the first triptan dose does not help, do not take a second dose for the same attack (rizatriptan and naratriptan SmPCs, AEMPS, section 4.2). Rizatriptan is contraindicated in moderately severe or severe hypertension and in untreated mild hypertension, and naratriptan in moderate or severe hypertension and in uncontrolled mild hypertension (AEMPS, section 4.3). Monitor blood pressure during naratriptan treatment (naratriptan label, FDA, section 5.8). If chest pain and tightness suggest cardiac ischaemia, withhold further doses and assess the patient (rizatriptan and naratriptan SmPCs, AEMPS, section 4.4). Stop the triptan if heart rhythm disturbances occur (FDA labels, section 5.2). Taking triptans, ergotamine or a combination of them on 10 or more days a month may make headaches more frequent, even to the point of daily headache, and the overused drugs may then need to be withdrawn (FDA labels, section 5.6).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Naratriptán (nº registro 61828), sección 4.3 (2023)– AEMPS, CIMA, nº registro 61828 (Naramig 2,5 mg, Glaxo), revisión 11/2023 (fecha del documento en CIMA; la sección 10 indica junio 2020), secciones 4.3, 4.4 y 4.5
- FDA: Naratriptan tablets, Bionpharma (naratriptan) prescribing information (2026)– FDA, DailyMed setid 93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda, revisión 06/2026 (versión 4), secciones 4, 5.1–5.8 y 7.1
- AEMPS: Ficha técnica: Rizatriptán (nº registro 62289), sección 4.3 (2024)– AEMPS, CIMA, nº registro 62289 (Maxalt 10 mg comprimidos, Organon Salud), revisión 07/2024, secciones 4.3, 4.4 y 4.5
- FDA: MAXALT (rizatriptan benzoate) prescribing information (2026)– FDA, DailyMed setid 007b4644-e0e7-4863-9ae3-fe09676b3f5f (Organon), revisión 01/2026 (versión 4), secciones 4, 5.2, 5.5, 5.6, 5.8 y 7.2